Publications

Oncotarget

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.

26-12-2017

Journal of the National Cancer Institute

Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.

01-12-2017

Breast cancer research and treatment

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.

01-12-2017

BMJ open

Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study.

14-11-2017

JCO precision oncology

Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer.

01-11-2017

The Lancet. Oncology

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.

01-11-2017

Contemporary clinical trials

Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.

01-10-2017

NPJ breast cancer

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

28-09-2017

Breast cancer research : BCR

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

25-08-2017

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.

20-08-2017

Drugs

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

01-08-2017

Cancer research

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.

15-07-2017

BMC cancer

Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).

01-07-2017

European journal of cancer (Oxford, England : 1990)

Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.

01-06-2017

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).

01-04-2017

European journal of cancer (Oxford, England : 1990)

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

01-03-2017

Proceedings of the National Academy of Sciences of the United States of America

Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.

21-02-2017

Breast cancer research and treatment

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.

01-02-2017

Cancer treatment reviews

(Very) Early technology assessment and translation of predictive biomarkers in breast cancer.

01-01-2017

Biomarker insights

Prognostic Value of MammaPrint^® in Invasive Lobular Breast Cancer.

17-12-2016

Breast (Edinburgh, Scotland)

Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute.

01-12-2016

Cancer

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.

01-10-2016

Breast (Edinburgh, Scotland)

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.

01-10-2016

Breast cancer research and treatment

Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

01-09-2016

International journal of cancer

BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.

15-08-2016

The Lancet. Oncology

10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study.

01-08-2016

Genetics in medicine : official journal of the American College of Medical Genetics

Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study.

01-07-2016

Cancer research

Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

01-07-2016

Breast cancer research and treatment

The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

01-07-2016

Cancer informatics

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.

28-06-2016

Trials

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.

21-06-2016

Oncotarget

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

07-06-2016

Nederlands tijdschrift voor geneeskunde

[Living with incurable cancer].

29-04-2016

Cell

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

07-04-2016

Breast cancer research and treatment

Equivalence of MammaPrint array types in clinical trials and diagnostics.

01-04-2016

Breast cancer research and treatment

Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period.

01-04-2016

Journal of proteome research

Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.

01-04-2016

Journal of neuro-oncology

Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.

01-04-2016

Oncotarget

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.

19-01-2016

Scientific reports

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

05-01-2016

Molecular oncology

4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.

01-01-2016

Molecular cancer therapeutics

High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.

01-01-2016

Cureus

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?

24-12-2015

Breast (Edinburgh, Scotland)

St. Gallen endocrine response classes predict recurrence rates over time.

01-12-2015

Genes, chromosomes & cancer

Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.

01-12-2015

Therapeutic drug monitoring

Dried Blood Spot Self-Sampling at Home for the Individualization of Tamoxifen Treatment: A Feasibility Study.

01-12-2015

Nature reviews. Clinical oncology

Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?

01-10-2015

Molecular oncology

BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

01-10-2015

BMC cancer

The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).

03-09-2015

BMC cancer

Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.

14-08-2015